There are currently 636 clinical trials in Austin, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including GSK Investigational Site, Dell Childrens Medical Center of Central Texas, Pfizer Investigational Site and University of Texas at Austin. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
05/20/2025
Locations: Research Site, Austin, Texas
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
NCT06555783
Recruiting
The purpose of this study is to measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/20/2025
Locations: Alkermes Investigator Site, Austin, Texas
Conditions: Narcolepsy Type 2
Register for Updates
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
NCT06767683
Recruiting
The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1) or Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/20/2025
Locations: Alkermes Investigational Site, Austin, Texas
Conditions: Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Register for Updates
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
NCT03242642
Recruiting
Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Heart Hospital of Austin, Austin, Texas
Conditions: Mitral Valve Regurgitation
Register for Updates
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) MASH
NCT06920043
Recruiting
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/19/2025
Locations: IMA Clinical Research - Austin, TX, Austin, Texas +2 locations
Conditions: Metabolic Dysfunction-Associated Steatohepatitis
Register for Updates
A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations
NCT06529419
Recruiting
A dose range-finding study to assess the efficacy and safety of multiple dose levels of AZD8630 administered via a dry powder inhaler in adults with uncontrolled asthma at risk of exacerbations, receiving medium -to -high dose inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/19/2025
Locations: Research Site, Austin, Texas
Conditions: Asthma
Register for Updates
Avalus Ultra Post-Approval Study (PAS)
NCT06506903
Recruiting
The purpose of this study is to characterize the safety and effectiveness of the Medtronic Avalus Ultra aortic valve bioprosthesis in patients with aortic valve disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Heart Hospital of Austin, Austin, Texas
Conditions: Aortic Valve Disease
Register for Updates
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06571045
Recruiting
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME) In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be ente... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Austin, TX, Austin, Texas
Conditions: Diabetic Macular Edema (DME)
Register for Updates
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
NCT06809595
Recruiting
A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Panorama
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
05/19/2025
Locations: Austin Clinical Trial Partners, Austin, Texas
Conditions: Generalized Anxiety Disorder
Register for Updates
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
NCT06456593
Recruiting
This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase. The objective is to evaluate the efficacy and safety of obefazimod compared to placebo as induction and maintenance therapy in subjects with moderately to severely active CD after inadequate response (no response, loss of response, or intolerance) to conventional therapies and/or advanced therapies. The primary objective for the 48-Week Extension Phase is to evaluate the sa... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/19/2025
Locations: Central Texas Clinical Research, LLC, Austin, Texas
Conditions: Moderately to Severely Active Crohn Disease
Register for Updates
A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)
NCT06941844
Recruiting
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Major Depressive Disorder - Emerge
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
05/19/2025
Locations: Dell Medical School, University of Texas at Austin, Austin, Texas +1 locations
Conditions: Major Depressive Disorder
Register for Updates
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06957080
Recruiting
EYE-RES-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME). In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be ent... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Austin, TX, Austin, Texas
Conditions: Diabetic Macular Edema (DME)
Register for Updates